- Home
- About Us
- Service
- Application
- Technology
- Contact Us
HapOnco® WESPlus
HapOnco® WESPlus
Solid Tumor Clinical Whole - Exome Sequencing
Product Introduction
HapOnco® WESPlus is a high - throughput gene testing product independently developed by HaploX, providing solid tumor patients with high - standard whole - exome sequencing, big data analysis, and professional medical interpretation for precise clinical diagnosis and treatment guidance. With a large number of sites, wide range, and comprehensive information, apOnco®WESPlus provides a comprehensive assessment of the tumor genome and offers comprehensive drug - use guidance. The rich testing content can better assist clinical treatment decisions and promote the translation of medical research.
Product Advantages
（1）Comprehensive Treatment Guidance: HapOnco®WESPlus covers important tumor - related regions, including comprehensive information on targeted therapy, immunotherapy, endocrine therapy, chemotherapy, hereditary tumors, and viral infections. It provides multidimensional and precise assessment of treatment efficacy and comprehensive guidance for tumor treatment plans.
（2）Enhanced Targeting: The probe design of HapOnco®WESPlus includes the whole exome, has a multiple - fold increase in probes targeting regions related to targeted and immune - related drug - use genes, ensuring that patients accurately obtain mutation information of important sites to assist clinical treatment decisions.
（3）Proven Efficacy: As a flagship product of HaploX, HapOnco®WESPlus has undergone long - term clinical validation. The company has collaborated with numerous hospitals to promote scientific research projects, with many results published in top - tier journals, including but not limited to Advanced Science and Nature Communications.
（2）Enhanced Targeting: The probe design of HapOnco®WESPlus includes the whole exome, has a multiple - fold increase in probes targeting regions related to targeted and immune - related drug - use genes, ensuring that patients accurately obtain mutation information of important sites to assist clinical treatment decisions.
（3）Proven Efficacy: As a flagship product of HaploX, HapOnco®WESPlus has undergone long - term clinical validation. The company has collaborated with numerous hospitals to promote scientific research projects, with many results published in top - tier journals, including but not limited to Advanced Science and Nature Communications.
Applicable Population
Patients with solid tumors who are planning to undergo targeted drug therapy, immunosuppressive therapy, chemotherapy, or endocrine therapy.Patients with solid tumors who need a comprehensive evaluation of immunosuppressive drug use, efficacy, and prognosis, or who need to understand resistance mechanisms, especially rare resistance mechanisms.Patients with solid tumors that are negative for typica ldriver gene mutations.Patients with solid tumors of unknown primary origin,multiple tumors or metastases throughout the body, a family history of cancer, or those who are difficult to diagnose.
Address
Units 610, 6/F, Building 16W, Phase 3, HongKong Science Park, New Territories, HongKong
Phone
+852 69410851
customer_service@haplox.net
© Copyright Job Portal 2025.
